N-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patients

Yonsei Medical Journal

Volumn 49, Issue 4, 2008, Pages 625-631

  Woo, Jeong Joo ^a   Koh, Young Youp ^b   Kim, Hee Joong ^c   Chung, Joong Wha ^b   Chan, Kyoung Sig ^b   Hong, Soon Pyo ^c  

^a Eulji General Hospital   (South Korea)

^b Chosun University College of Medicine   (South Korea)

^c Hwasun Korea Hospital   (South Korea)

Author keywords

Cardiac dysfunction; Cirrhosis; N terminal proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; ASCITES; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE FUNCTION; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL;

ADULT; AGED; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN;

EID: 52949099517     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2008.49.4.625     Document Type: Article

References (30)

1. Llach J, Ginès P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94: 482-7.
2. Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997;17:505-19.
3. Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000;140:111-20.
4. Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med 1989;151:530-5.
5. Baik SK, Lee SS. Cirrhotic cardiomyopathy: causes and consequences. J Gastroenterol Hepatol Suppl 2004;7: S185-90.
6. Epstein SK, Ciubotaru RL, Zilberberg MD, Kaplan LM, Jacoby C, Freeman R, et al. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci 1998;43:1701-7.
7. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000;32:859-65.
8. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451-9.
9. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
10. La Villa G, Romanelli RG, Casini Raggi V, Tosti Guerra C, De Feo ML, Marra F, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 1992;16:156-61.
11. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) 2001;101:621-8.
12. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-7.
13. Campell DJ, Mitchelhill KI, Schlicht SM, Booth RJ. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction. J Card Fail 2000;6:130-9.
14. Gøtze JP, Kastrup J. Plasma pro-brain natriuretic peptides are strong biochemical markers in clinical cardiology. Scand J Clin Lab Invest Suppl 2001;234: 47-51.
15. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: A diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003;4:72-80.
16. Gould L, Zahir M, Shariff M, DiLieto M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969;48: 860-8.
17. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974;49: 754-60.
18. Hu W, Sun X, He J, Ma Y, Wang L. The study by echocardiography in 44 patients with cirrhotic cardiomyopathy. J Gastroenterol Hepatol Suppl 2004;5:A653.
19. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
20. Mann DL. Mechanisms and models of heart failure: a combinational approach. Circulation 1999;100:999-1008
21. Mair J. Monitoring of patients with heart failure. Scand J Clin Lab Invest Suppl 2005;240:99-106.
22. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999;97: 259-67.
23. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996;31:279-84.
24. Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006;3:329-37.
25. Alexander J, Mishra P, Desai N, Ambadekar S, Gala B, Sawant P. Cirrhotic cardiomyopathy: Indian scenario. J Gastroenterol Hepatol 2007;22:395-9.
26. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88.
27. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation 2003;108:2950-3.
28. Yu CM, Sanderson JE. Plasma brain natriuretic peptide - an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1999;1:59-65.
29. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. NT-proBNP in severe chronic heart failure: rationale, design, and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004;6:343-50.
30. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.